论文部分内容阅读
对16例接受等容血液稀释治疗及15例接受常规治疗的急性脑梗塞患者分别在治疗前、治疗后第5d和第30d检测血浆激肽释放酶原(PK)、蛋白C(PC)和蛋白S(PS)含量,并以20名健康者作正常对照。结果显示,治疗前两组患者各项指标均在正常范围,治疗后第5d稀释治疗组血浆PK含量显著下降(P<0.05),治疗后第30d稀释治疗组PC含量显著下降(P<0.05),未经稀释治疗的病例其相应指标无显著性变化。提示血液稀释疗法可能有提高脑梗塞患者抗凝系统的活性及调节凝血系统和抗凝系统平衡的作用。
Sixteen patients with acute cerebral infarction who received isovolemic hemodilution and 15 patients who received conventional therapy were tested for plasma levels of kallikrein (PK), protein C (PC) and protein before treatment, 5 days and 30 days after treatment S (PS) content, and 20 healthy people as a normal control. The results showed that, before treatment, the indexes of two groups were within the normal range, and the content of PK in the diluted group on the 5th day after treatment was significantly decreased (P <0.05). The PC content in the diluted group on the 30th day after treatment was significantly decreased (P <0.05) , Undifferentiated cases of treatment of its corresponding index no significant change. It is suggested that hemodilution therapy may improve the anticoagulant activity of patients with cerebral infarction and regulate the balance of the coagulation system and anticoagulation system.